Page 1 | Search Results | Blood | American Society of Hematology

1-8 of 8

Sort by

Sort Order Select

Journal Articles

The Use of Avapritinib in Advanced Systemic Mastocytosis: Report of an Open-Label Compassionate Use Program in the United Kingdom

Christopher J. Saunders, Chandan Saha, Priya Sriskandarajah, Helen Cashman, Andrew J Wilson, Jonathan Lambert, Matthew Lawes, David Tucker, Simone Green, Manish Jain, Victoria Stables, Juanah Addada, Theingi Yin, Huw Roddie, Bethan Psaila, Deepti H. Radia

Blood (2022) 140 (Supplement 1): 3976–3977.

https://doi.org/10.1182/blood-2022-166073

Published: 2022

Journal Articles

Apixaban Is Safe and Effective Thromboprophylaxis in Myeloma Patients Treated with Immunomodulatory Therapy

Neill Storrar, MBBChir, Abhinav Mathur, MBChB, Peter Johnson, MD, Huw Roddie, PhD

Blood (2017) 130 (Supplement 1): 1872.

https://doi.org/10.1182/blood.V130.Suppl_1.1872.1872

Published: 2017

Journal Articles

Retrospective Matched-Pair Analysis Of The Efficacy and Safety Of Bortezomib Plus Dexamethasone Versus Bortezomib Monotherapy In Patients (Pts) With Relapsed Multiple Myeloma (MM)

Meletios A. Dimopoulos, MD, Robert Z. Orlowski, M.D., Ph.D, Thierry Facon, MD, Pieter Sonneveld, MD, Ph.D, Kenneth C. Anderson, MD, Meral Beksac, MD, Lotfi Benboubker, MD, Huw Roddie, MBChB, Ph.D, Anna Potamianou, MD, Catherine Couturier, PharmD, Huaibao Feng, Ph.D, Ozlem Ataman, MD, Ph.D, Helgi van de Velde, Paul G. Richardson, MD

Blood (2013) 122 (21): 3177.

https://doi.org/10.1182/blood.V122.21.3177.3177

Published: 2013

Journal Articles

The role of maintenance thalidomide therapy in multiple myeloma: MRC Myeloma IX results and meta-analysis

Gareth J. Morgan, Walter M. Gregory, Faith E. Davies, Sue E. Bell, Alexander J. Szubert, Julia M. Brown, Nuria N. Coy, Gordon Cook, Nigel H. Russell, Claudius Rudin, Huw Roddie, Mark T. Drayson, Roger G. Owen, Fiona M. Ross, Graham H. Jackson, J. Anthony Child, on behalf of the National Cancer Research Institute Haematological Oncology Clinical Studies Group

Blood (2012) 119 (1): 7–15.

https://doi.org/10.1182/blood-2011-06-357038

Published: 2012

Includes: Supplemental data

Journal Articles

Bortezomib-Dexamethasone Alone or Plus Cyclophosphamide or Lenalidomide As Second-Line Treatment for Patients with Multiple Myeloma: Final Results From a Phase 2 Study

Meletios Athanasios Dimopoulos, MD, Meral Beksac, MD, Lotfi Benboubker, MD, PhD, Huw Roddie, MBChB, PhD, Nathalie Allietta, Esther Broer, Catherine Couturier, PharmD, Marie-Andrée Mazier, DESS, Ralf Angermund, MD, Thierry Facon, MD

Blood (2011) 118 (21): 1861.

https://doi.org/10.1182/blood.V118.21.1861.1861

Published: 2011

Journal Articles

Cyclophosphamide, thalidomide, and dexamethasone (CTD) as initial therapy for patients with multiple myeloma unsuitable for autologous transplantation

Gareth J. Morgan, Faith E. Davies, Walter M. Gregory, Nigel H. Russell, Sue E. Bell, Alexander J. Szubert, Nuria Navarro Coy, Gordon Cook, Sylvia Feyler, Jenny L. Byrne, Huw Roddie, Claudius Rudin, Mark T. Drayson, Roger G. Owen, Fiona M. Ross, Graham H. Jackson, J. Anthony Child, for the NCRI Haematological Oncology Study Group

Blood (2011) 118 (5): 1231–1238.

https://doi.org/10.1182/blood-2011-02-338665

Published: 2011

Includes: Supplemental data

Journal Articles

A Randomized Phase 2 Trial of Bortezomib–Dexamethasone Versus Bortezomib–Dexamethasone with Added Cyclophosphamide or Lenalidomide in Multiple Myeloma Patients Achieving Stable Disease After Four Cycles of Bortezomib–Dexamethasone Administered as Second-Line Treatment.

Meletios A. Dimopoulos, Huw Roddie, Meral Beksac, Lotfi Benboubker, Romualdas Jurgutis, Christian Langer, Javier de la Rubia, Luis Felipe Casado, Kazimierz Kuliczkowski, Lena Macukanovic-Golubovic, Thierry Facon

Blood (2009) 114 (22): 4937.

https://doi.org/10.1182/blood.V114.22.4937.4937

Published: 2009

Journal Articles

Lenalidomide Enhances Leukaemia Specific T Cell Responses to Dendritic Cell Based Immunotherapy for Myeloid Leukaemias.

Caroline J Duncan, MBBS, MRCP(Ed), Peter R. E. Johnson, MD, Huw Roddie, MBChB, PhD

Blood (2008) 112 (11): 1954.

https://doi.org/10.1182/blood.V112.11.1954.1954

Published: 2008

NARROW

The Use of Avapritinib in Advanced Systemic Mastocytosis: Report of an Open-Label Compassionate Use Program in the United Kingdom

Apixaban Is Safe and Effective Thromboprophylaxis in Myeloma Patients Treated with Immunomodulatory Therapy

Retrospective Matched-Pair Analysis Of The Efficacy and Safety Of Bortezomib Plus Dexamethasone Versus Bortezomib Monotherapy In Patients (Pts) With Relapsed Multiple Myeloma (MM)

The role of maintenance thalidomide therapy in multiple myeloma: MRC Myeloma IX results and meta-analysis

Bortezomib-Dexamethasone Alone or Plus Cyclophosphamide or Lenalidomide As Second-Line Treatment for Patients with Multiple Myeloma: Final Results From a Phase 2 Study

Cyclophosphamide, thalidomide, and dexamethasone (CTD) as initial therapy for patients with multiple myeloma unsuitable for autologous transplantation

A Randomized Phase 2 Trial of Bortezomib–Dexamethasone Versus Bortezomib–Dexamethasone with Added Cyclophosphamide or Lenalidomide in Multiple Myeloma Patients Achieving Stable Disease After Four Cycles of Bortezomib–Dexamethasone Administered as Second-Line Treatment.

Lenalidomide Enhances Leukaemia Specific T Cell Responses to Dendritic Cell Based Immunotherapy for Myeloid Leukaemias.

Email alerts

ASH Publications

American Society of Hematology

Email alerts

ASH Publications

American Society of Hematology

This Feature Is Available To Subscribers Only